Atrial fibrillation ablation: A cost or an investment?

Josef Kautzner, Veronika Bulkova, Gerhard Hindricks, Nikos Maniadakis, Paolo Della Bella, Pierre Jaïs, Karl Heinz Kuck

Research output: Contribution to journalArticle

Abstract

In the last decade, catheter ablation (CA) became a viable therapeutic approach for symptomatic patients with atrial fibrillation (AF) non-responsive to antiarrhythmic drugs (AAD). The economic analysis of CA is complex due to the presence of several confounding factors, such as the pattern of AF (paroxysmal AF, persistent or long-term persistent AF), the patient population (age, presence/absence of underlying structural heart disease, comorbidities, etc.), the different techniques for ablation (with impact on complexity and cost of the procedure, as well as on efficacy and safety), and the learning curve and experience of an individual centre (with impact on efficacy and cost effectiveness). At present, CA appears to be cost effective mainly in patients with paroxysmal AF who are refractory to AADs, especially if the success of the procedure and, thus, the benefit in quality of life remains >5 years, with a low complication rate. More data are needed on cost effectiveness of CA of persistent and long-term persistent AF or of AF associated with heart failure. Atrial fibrillation ablation is unlikely to be cost effective for patients who have preserved quality of life despite their AF or for patients whose quality of life is not expected to improve substantially despite elimination of AF (e.g. patients with poor quality of life mainly due to other health problems). These observations may help in the selection of candidates for AF ablation.

Original languageEnglish
JournalEuropace
Volume13
Issue numberSUPPL. 2
DOIs
Publication statusPublished - May 2011

Fingerprint

Atrial Fibrillation
Costs and Cost Analysis
Catheter Ablation
Quality of Life
Cost-Benefit Analysis
Ablation Techniques
Learning Curve
Anti-Arrhythmia Agents
Comorbidity
Heart Diseases
Heart Failure
Economics
Safety
Health

Keywords

  • Ablation
  • Atrial fibrillation
  • Cost
  • Cost effectiveness
  • Quality of life

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Kautzner, J., Bulkova, V., Hindricks, G., Maniadakis, N., Della Bella, P., Jaïs, P., & Kuck, K. H. (2011). Atrial fibrillation ablation: A cost or an investment? Europace, 13(SUPPL. 2). https://doi.org/10.1093/europace/eur084

Atrial fibrillation ablation : A cost or an investment? / Kautzner, Josef; Bulkova, Veronika; Hindricks, Gerhard; Maniadakis, Nikos; Della Bella, Paolo; Jaïs, Pierre; Kuck, Karl Heinz.

In: Europace, Vol. 13, No. SUPPL. 2, 05.2011.

Research output: Contribution to journalArticle

Kautzner, J, Bulkova, V, Hindricks, G, Maniadakis, N, Della Bella, P, Jaïs, P & Kuck, KH 2011, 'Atrial fibrillation ablation: A cost or an investment?', Europace, vol. 13, no. SUPPL. 2. https://doi.org/10.1093/europace/eur084
Kautzner J, Bulkova V, Hindricks G, Maniadakis N, Della Bella P, Jaïs P et al. Atrial fibrillation ablation: A cost or an investment? Europace. 2011 May;13(SUPPL. 2). https://doi.org/10.1093/europace/eur084
Kautzner, Josef ; Bulkova, Veronika ; Hindricks, Gerhard ; Maniadakis, Nikos ; Della Bella, Paolo ; Jaïs, Pierre ; Kuck, Karl Heinz. / Atrial fibrillation ablation : A cost or an investment?. In: Europace. 2011 ; Vol. 13, No. SUPPL. 2.
@article{8139d5ddeadc472181184450f4319929,
title = "Atrial fibrillation ablation: A cost or an investment?",
abstract = "In the last decade, catheter ablation (CA) became a viable therapeutic approach for symptomatic patients with atrial fibrillation (AF) non-responsive to antiarrhythmic drugs (AAD). The economic analysis of CA is complex due to the presence of several confounding factors, such as the pattern of AF (paroxysmal AF, persistent or long-term persistent AF), the patient population (age, presence/absence of underlying structural heart disease, comorbidities, etc.), the different techniques for ablation (with impact on complexity and cost of the procedure, as well as on efficacy and safety), and the learning curve and experience of an individual centre (with impact on efficacy and cost effectiveness). At present, CA appears to be cost effective mainly in patients with paroxysmal AF who are refractory to AADs, especially if the success of the procedure and, thus, the benefit in quality of life remains >5 years, with a low complication rate. More data are needed on cost effectiveness of CA of persistent and long-term persistent AF or of AF associated with heart failure. Atrial fibrillation ablation is unlikely to be cost effective for patients who have preserved quality of life despite their AF or for patients whose quality of life is not expected to improve substantially despite elimination of AF (e.g. patients with poor quality of life mainly due to other health problems). These observations may help in the selection of candidates for AF ablation.",
keywords = "Ablation, Atrial fibrillation, Cost, Cost effectiveness, Quality of life",
author = "Josef Kautzner and Veronika Bulkova and Gerhard Hindricks and Nikos Maniadakis and {Della Bella}, Paolo and Pierre Ja{\"i}s and Kuck, {Karl Heinz}",
year = "2011",
month = "5",
doi = "10.1093/europace/eur084",
language = "English",
volume = "13",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Atrial fibrillation ablation

T2 - A cost or an investment?

AU - Kautzner, Josef

AU - Bulkova, Veronika

AU - Hindricks, Gerhard

AU - Maniadakis, Nikos

AU - Della Bella, Paolo

AU - Jaïs, Pierre

AU - Kuck, Karl Heinz

PY - 2011/5

Y1 - 2011/5

N2 - In the last decade, catheter ablation (CA) became a viable therapeutic approach for symptomatic patients with atrial fibrillation (AF) non-responsive to antiarrhythmic drugs (AAD). The economic analysis of CA is complex due to the presence of several confounding factors, such as the pattern of AF (paroxysmal AF, persistent or long-term persistent AF), the patient population (age, presence/absence of underlying structural heart disease, comorbidities, etc.), the different techniques for ablation (with impact on complexity and cost of the procedure, as well as on efficacy and safety), and the learning curve and experience of an individual centre (with impact on efficacy and cost effectiveness). At present, CA appears to be cost effective mainly in patients with paroxysmal AF who are refractory to AADs, especially if the success of the procedure and, thus, the benefit in quality of life remains >5 years, with a low complication rate. More data are needed on cost effectiveness of CA of persistent and long-term persistent AF or of AF associated with heart failure. Atrial fibrillation ablation is unlikely to be cost effective for patients who have preserved quality of life despite their AF or for patients whose quality of life is not expected to improve substantially despite elimination of AF (e.g. patients with poor quality of life mainly due to other health problems). These observations may help in the selection of candidates for AF ablation.

AB - In the last decade, catheter ablation (CA) became a viable therapeutic approach for symptomatic patients with atrial fibrillation (AF) non-responsive to antiarrhythmic drugs (AAD). The economic analysis of CA is complex due to the presence of several confounding factors, such as the pattern of AF (paroxysmal AF, persistent or long-term persistent AF), the patient population (age, presence/absence of underlying structural heart disease, comorbidities, etc.), the different techniques for ablation (with impact on complexity and cost of the procedure, as well as on efficacy and safety), and the learning curve and experience of an individual centre (with impact on efficacy and cost effectiveness). At present, CA appears to be cost effective mainly in patients with paroxysmal AF who are refractory to AADs, especially if the success of the procedure and, thus, the benefit in quality of life remains >5 years, with a low complication rate. More data are needed on cost effectiveness of CA of persistent and long-term persistent AF or of AF associated with heart failure. Atrial fibrillation ablation is unlikely to be cost effective for patients who have preserved quality of life despite their AF or for patients whose quality of life is not expected to improve substantially despite elimination of AF (e.g. patients with poor quality of life mainly due to other health problems). These observations may help in the selection of candidates for AF ablation.

KW - Ablation

KW - Atrial fibrillation

KW - Cost

KW - Cost effectiveness

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=79955611687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955611687&partnerID=8YFLogxK

U2 - 10.1093/europace/eur084

DO - 10.1093/europace/eur084

M3 - Article

C2 - 21518748

AN - SCOPUS:79955611687

VL - 13

JO - Europace

JF - Europace

SN - 1099-5129

IS - SUPPL. 2

ER -